Showing results (21-30 of 170) with videos related to
Sort By:
Pageof 17
Chemistry & Biodiversity|September 15, 2012
Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicityBjörn R Hoffmeister, Mahsa S Adib-Razavi, Michael A Jakupec, et al.Dalton Transactions (Cambridge, England : 2003)|December 22, 2009
Synthesis and biological studies of some gold(I) complexes containing functionalised alkynesEsther Schuh, Seied M Valiahdi, Michael A Jakupec, et al.Chemical Communications (Cambridge, England)|July 17, 2012
Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugsVladimir B Arion, Anatolie Dobrov, Simone Göschl, et al.Dalton Transactions (Cambridge, England : 2003)|December 22, 2007
Antitumour metal compounds: more than theme and variationsMichael A Jakupec, Mathea S Galanski, Vladimir B Arion, et al.Metallomics : Integrated Biometal Science|January 26, 2016
LA-ICP-MS imaging in multicellular tumor spheroids - a novel tool in the preclinical development of metal-based anticancer drugsSarah Theiner, Ekaterina Schreiber-Brynzak, Michael A Jakupec, et al.Chemistryopen|February 25, 2022
Systematic Study on the Cytotoxic Potency of Commonly Used Dimeric Metal Precursors in Human Cancer Cell LinesHeiko Geisler, Sophia Harringer, Dominik Wenisch, et al.Journal of Inorganic Biochemistry|October 6, 2012
Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cellsGerhard Mühlgassner, Caroline Bartel, Wolfgang F Schmid, et al.Journal of Analytical Atomic Spectrometry|June 23, 2012
Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cellsAlexander E Egger, Christina Rappel, Michael A Jakupec, et al.Inorganic Chemistry|October 29, 2010
Structure-activity relationships of highly cytotoxic copper(II) complexes with modified indolo[3,2-c]quinoline ligandsMichael F Primik, Simone Göschl, Michael A Jakupec, et al.Journal of Inorganic Biochemistry|April 11, 2006
From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)Christian G Hartinger, Stefanie Zorbas-Seifried, Michael A Jakupec, et al.Pageof 17